Iovance, A Top 1% Biotech Stock, Crashes In A Surprise Lung Cancer Twist

Live updates

1. 1h ago

   Iovance Shares Plummet After Phase 2 Lung Cancer Trial Data

   Iovance Biotherapeutics shares crashed Thursday following updated Phase 2 IOV-LUN-202 trial data for lifileucel in patients with metastatic non-small-cell lung cancer. While the company described the data as positive and consistent with previous results, investors reacted to new durability questions, causing the stock to sink 31% in one instance and trigger its worst day in over 17 months. Baird responded to the data by cutting its price target to $9, leading to a further 11% decline. Some retail investors suggest that selling may not be finished.

   Why it matters

   Iovance specializes in Tumor Infiltrating Lymphocyte therapy, which has previously targeted melanoma. Expanding this precision medicine strategy into lung cancer is a key growth driver for the company. The stock's volatility reflects the high stakes of trial durability in the biotech sector.

   What is confirmed

   • Iovance reported updated results from its Phase 2 IOV-LUN-202 trial evaluating lifileucel in patients with metastatic non-small-cell lung cancer.
   • The stock experienced its worst day in over 17 months.
   • Baird reduced its price target for Iovance to $9 following the lung cancer data.
   • The company described the lung cancer TIL data as consistent with previously reported results.

   Still unconfirmed

   • Iovance stock could potentially fall 50%.
   • The stock jumped over 10% in after-hours trading.

   What to watch next

   • Further analysis of the lifileucel durability data in mNSCLC patients
   • Updates on the broader precision medicine strategy mentioned in the company webcast
   • Potential revisions to analyst price targets beyond the Baird cut
   Sources used for this update (20)

   1. Investor's Business Daily — Iovance, A Top 1% Biotech Stock, Crashes In A Surprise Lung Cancer Twist
   2. Yahoo Finance — IOVA Stock Heads For Worst Day In Over 17 Months, Retail Says ‘Selling Is Not Done’ – What’s Driving The Fall?
   3. Trefis — Can Iovance Stock Fall 50%?
   4. Investing.com — Why is Iovance Biotherapeutics stock sliding today?
   5. TradingView — Why Did IOVA Stock Jump Over 10% After-Hours Today?
   6. Yahoo Finance — Melanoma Trial Results Could Be A Game Changer For Iovance Biotherapeutics (IOVA)
   7. Seeking Alpha — Iovance plummets on new phase 2 Amtagvi data for non-small-cell lung cancer
   8. GlobeNewswire — Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Broader Precision Medicine Strategy
   9. TIKR.com — Iovance Sinks 31% as Lung Cancer TIL Data Comes In “Consistent With Previously Reported Results”
   10. Trefis — Is 50% Crash Risk For Iovance Stock Real?
   11. The ASCO Post — TIL Therapy Plus Pembrolizumab for Advanced Melanoma
   12. TIKR.com — Iovance Sinks Another 11% as Baird Cuts Target to $9 After Lung Cancer Data
   confidence 90%